Ivana Barun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ivana Barun has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandar Kirkovski
Faculty of Medicine, Ss. Cyril and Methodius University , Skopje, North Macedonia
1 shared publication - Andrija Babić
Institute of Emergency Medicine in Split-Dalmatia County, Split, Croatia
1 shared publication - Anđela Pijuk
Division of Hematology, Department of Internal Medicine University Hospital of Split Split Croatia
1 shared publication - Daiana Anne‐Marie Dimcea
Department of Obstetrics and Gynaecology Elias Emergency University Hospital Bucharest Romania
1 shared publication - Frano Šarić
Clinical Department of Diagnostic and Interventional Radiology, University Hospital of Split, Spinčićeva 1, 21000 Split, Croatia
1 shared publication - Hrvoje Lukić1 shared publication
Latest Publications
- 1 March 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (1-2) , 35
Superficial temporal artery access for coronary angiography
- 1 March 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (1-2) , 35
Superficial temporal artery access for coronary angiography
- 23 January 2024
- Published by Wiley in Research Synthesis Methods
- Vol. 15 (3) , 430-440
Frequency of use and adequacy of Cochrane risk of bias tool 2 in non‐Cochrane systematic reviews published in 2020: Meta‐research study
Risk of bias (RoB) assessment is essential to the systematic review methodology. The new version of the Cochrane RoB tool for randomized trials (RoB 2) was published in 2019 to address limitations identified since the first version of the tool was published in 2008 and to increase the reliability of assessments. This study analyzed the frequency of usage of the RoB 2 and the adequacy of reporting the RoB 2 assessments in non‐Cochrane reviews published in 2020. This meta‐research study included non‐Cochrane systematic reviews of interventions published in 2020. For the reviews that used the RoB 2 tool, we analyzed the reporting of the RoB 2 assessment. Among 3880 included reviews, the Cochrane RoB 1 tool was the most frequently used (N = 2228; 57.4%), followed by the Cochrane RoB 2 tool (N = 267; 6.9%). From 267 reviews that reported using the RoB 2 tool, 213 (79.8%) actually used it. In 26 (12.2%) reviews, erroneous statements were used to indicate the RoB 2 assessment. Only 20 (9.4%) reviews presented a complete RoB 2 assessment with a detailed table of answers to all signaling questions. The judgment of risk of bias by the RoB 2 tool was not justified by a comment in 158 (74.2%) reviews. Only in 33 (14.5%) of reviews the judgment in all domains was justified in the accompanying comment. In most reviews (81.7%), the RoB was inadequately assessed at the study level. In conclusion, the majority of non‐Cochrane reviews published in 2020 still used the Cochrane RoB 1 tool. Many reviews used the RoB 2 tool inadequately. Further studies about the uptake and the use of the RoB 2 tool are needed.
- 23 January 2024
- Published by Wiley in Research Synthesis Methods
- Vol. 15 (3) , 430-440
Frequency of use and adequacy of Cochrane risk of bias tool 2 in non‐Cochrane systematic reviews published in 2020: Meta‐research study
Risk of bias (RoB) assessment is essential to the systematic review methodology. The new version of the Cochrane RoB tool for randomized trials (RoB 2) was published in 2019 to address limitations identified since the first version of the tool was published in 2008 and to increase the reliability of assessments. This study analyzed the frequency of usage of the RoB 2 and the adequacy of reporting the RoB 2 assessments in non‐Cochrane reviews published in 2020. This meta‐research study included non‐Cochrane systematic reviews of interventions published in 2020. For the reviews that used the RoB 2 tool, we analyzed the reporting of the RoB 2 assessment. Among 3880 included reviews, the Cochrane RoB 1 tool was the most frequently used (N = 2228; 57.4%), followed by the Cochrane RoB 2 tool (N = 267; 6.9%). From 267 reviews that reported using the RoB 2 tool, 213 (79.8%) actually used it. In 26 (12.2%) reviews, erroneous statements were used to indicate the RoB 2 assessment. Only 20 (9.4%) reviews presented a complete RoB 2 assessment with a detailed table of answers to all signaling questions. The judgment of risk of bias by the RoB 2 tool was not justified by a comment in 158 (74.2%) reviews. Only in 33 (14.5%) of reviews the judgment in all domains was justified in the accompanying comment. In most reviews (81.7%), the RoB was inadequately assessed at the study level. In conclusion, the majority of non‐Cochrane reviews published in 2020 still used the Cochrane RoB 1 tool. Many reviews used the RoB 2 tool inadequately. Further studies about the uptake and the use of the RoB 2 tool are needed.